Journal of Clinical Oncology, Vol 23, No 15 (May 20), 2005: pp. 3517-3525
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.07.044
Clinical Value of Mitochondrial Mutations in Colorectal Cancer
Astrid Lièvre,
Caroline Chapusot,
Anne-Marie Bouvier,
Franck Zinzindohoué,
Françoise Piard,
Patrick Roignot,
Laurent Arnould,
Philippe Beaune,
Jean Faivre,
Pierre Laurent-Puig
From the Institut National de Santé et de la Recherche Médicale (INSERM) U490, Laboratoire de Toxicologie Moléculaire; Pôle de Cancérologie, Hôpital Européen Georges Pompidou, Paris; Centre Hospitalier Universitaire (CHU) Dijon, Service d'Anatomo-Pathologie; INSERM Equipe Mixte INSERM (EMI) 0106, CHU, Registre Bourguignon des Tumeurs; Centre de Pathologie, Rue Nicolas Bornier; Centre Georges François Leclerc, Service d'Anatomo-Pathologie, Dijon, France
Address reprint requests to Pierre Laurent-Puig, INSERM U490 Laboratoire de Toxicologie Moléculaire, 45 Rue des Saints Pères, 75006 Paris, France; e-mail: pierre.laurent-puig{at}biomedicale.univ-paris5.fr
PURPOSE: Prognostic factors that could select high-risk recurrence colorectal cancer patients and predict chemosensitivity are needed. Since mutations of mitochondrial DNA (mtDNA) have been described in different types of cancers and since they may play a role in response to anticancer agents, we investigated in a population-based series of colorectal cancer patients the clinical value of mtDNA mutations.
PATIENTS AND METHODS: The displacement loop (D-loop) region of mtDNA was sequenced on a series of 365 patients recorded in the Digestive Cancer Registry of Côte-d'Or (France) between 1998 and 2000. Clinicopathologic characteristics were correlated to the presence of a D-loop mutation. Survival rates were compared with the log-rank test. A multivariate survival analysis was performed.
RESULTS: D-loop mutations were found in 38.3% of the tumors. The 3-year survival rate was 53.5% in patients with D-loop mutation versus 62.1% in patients without (P = .05). After adjustment for age, stage, and microsatellite instability status, the relative risk of death in patients with D-loop mutation was 1.40 (95% CI, 1.02 to 1.93; P = .034) as compared with those without. In stage III colon cancers, adjuvant chemotherapy was beneficial only for patients without D-loop mutation (3-year survival, 78.3% v 45.4%, P < .02). In those with D-loop mutation who received adjuvant chemotherapy, the relative risk of death was 4.30 (95% CI, 1.23 to 15.00; P < .02).
CONCLUSION: The D-loop region is a hotspot for somatic mutations in colorectal tumors. Moreover, presence of tumor D-loop mutation appears to be a factor of poor prognosis in colorectal patients and a factor of resistance to fluorouracil-based adjuvant chemotherapy in stage III colon cancers.
Supported by L'Association de Recherche Contre le Cancer (ARC No. 3329); La Société Nationale Française de Gastroentérologie; La Region Ile de France, La Fondation de France, Paris, France.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
C. Ye, Y.-T. Gao, W. Wen, J. P. Breyer, X. O. Shu, J. R. Smith, W. Zheng, and Q. Cai
Association of Mitochondrial DNA Displacement Loop (CA)n Dinucleotide Repeat Polymorphism with Breast Cancer Risk and Survival among Chinese Women
Cancer Epidemiol. Biomarkers Prev.,
August 1, 2008;
17(8):
2117 - 2122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-Y. Hung, J.-C. Lin, L.-M. Lee, C.-W. Wu, L.-M. Tseng, P.-H. Yin, C.-W. Chi, and H.-C. Lee
Tandem duplication/triplication correlated with poly-cytosine stretch variation in human mitochondrial DNA D-loop region
Mutagenesis,
March 1, 2008;
23(2):
137 - 142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Gasparre, A. M. Porcelli, E. Bonora, L. F. Pennisi, M. Toller, L. Iommarini, A. Ghelli, M. Moretti, C. M. Betts, G. N. Martinelli, et al.
Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors
PNAS,
May 22, 2007;
104(21):
9001 - 9006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Jacobs, M. Gerards, P. Chinnery, J. Dumoulin, I. de Coo, J. Geraedts, and H. Smeets
mtDNA point mutations are present at various levels of heteroplasmy in human oocytes
Mol. Hum. Reprod.,
March 1, 2007;
13(3):
149 - 154*.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Zhou, K. Kassauei, D. J. Cutler, G. C. Kennedy, D. Sidransky, A. Maitra, and J. Califano
An Oligonucleotide Microarray for High-Throughput Sequencing of the Mitochondrial Genome
J. Mol. Diagn.,
September 1, 2006;
8(4):
476 - 482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chen, Z. Yu, Z. Zhu, and C. D. Lopez
The p53 Pathway Promotes Efficient Mitochondrial DNA Base Excision Repair in Colorectal Cancer Cells.
Cancer Res.,
April 1, 2006;
66(7):
3485 - 3494.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|